Close Menu

Mass General

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

In Cell this week: systems biology analysis of inflammatory syndrome seen in children with COVID-19, single-cell RNA-sequencing strategies, and more.

The trial will use Natera's Signatera test to determine patient enrollment eligibility based on the presence of ctDNA and to evaluate response based on ctDNA clearance.

Accounting for polygenic background in conditions like hereditary breast cancer or Lynch syndrome can increase the accuracy of disease risk estimation.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.

The technology could be developed into therapies for diseases caused by DNA transversion point mutations, and used to conduct molecular research on such conditions.

In Nature this week: method for studying higher-order interactions among genes from single-cell data, and more.

Three research teams profiled proteomic, genomic, and other features in lung adenocarcinomas in Asia and other parts of the world, including cases in never-smokers.

Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.

Again and Again

SARS-CoV-2 was introduced into the Boston area multiple times, WBUR reports.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.